Clique

Clique Therapeutics is a Toronto-based biotechnology company focused on discovering and developing next-generation small molecule therapeutics that target difficult-to-treat protein-protein interactions (PPIs). The company utilizes its proprietary Mammalian Membrane Two-Hybrid (MaMTH) and Split-Intein Mediated Protein-Protein Interaction (SIMPL) platforms to identify inhibitors of oncogenic signaling pathways. Their primary focus is on developing treatments for various cancers, including those driven by KRAS and EGFR mutations. By targeting the physical interactions between proteins rather than just their enzymatic activity, Clique aims to overcome resistance mechanisms common in traditional therapies. The company's technology is particularly effective for membrane-associated proteins, which represent a significant portion of the human proteome but are often challenging to drug.